53 In a clinical trial, an overall more favorable trend for improving perceived sleep was observed in the NightWareTM treatment group; however, individual measures including sleep quality, PTSD symptoms, and quality of life across the 30‐day trial did not reach statistical significance between the NightWareTM and control groups. 53 Other FDA‐approved or EUA‐designated DTx for psychiatric disorders include EndeavorRx® for treating ADHD, Deprexis® for treating psychosis/depression, and SparkRx® for treating depression in adolescents (Table 1 ).
1
—
—